Jazz Pharmaceuticals to Participate in Upcoming November Investor Conferences

Jazz Pharmaceuticals to Participate in Upcoming November Investor Conferences

PR Newswire

DUBLIN, Nov. 9, 2021

Jefferies London Healthcare Conference

4th Annual Evercore ISI HealthCONx Conference

DUBLIN, Nov. 9, 2021 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will virtually participate in the following upcoming investor conferences:

Jefferies London Healthcare Conference on Tuesday, November 16, 2021

Evercore ISI HealthCONx Conference on Tuesday, November 30, 2021

Jazz will virtually participate in both conferences and webcasts of the presentations will be available via the Investors section of the Jazz Pharmaceuticals website at www.jazzpharma.com. Replays of the webcasts will be available on the website for 30 days.  

About Jazz Pharmaceuticals
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) is a global biopharmaceutical company whose purpose is to innovate to transform the lives of patients and their families. We are dedicated to developing life-changing medicines for people with serious diseases—often with limited or no therapeutic options. We have a diverse portfolio of marketed medicines and novel product candidates, from early- to late-stage development, in neuroscience and oncology. Within these therapeutic areas, we are identifying new options for patients by actively exploring small molecules and biologics, and through innovative delivery technologies and cannabinoid science. Jazz is headquartered in Dublin, Ireland and has employees around the globe, serving patients in nearly 75 countries. For more information, please visit www.jazzpharma.com and follow @JazzPharma on Twitter.


Andrea N. Flynn, Ph.D.
Vice President, Head, Investor Relations
Jazz Pharmaceuticals plc
Ireland +353 1 634 3211
U.S. +1 650 496 2717

Kristin Bhavnani
Head of Global Corporate Communications
Jazz Pharmaceuticals plc
Ireland +353 1 697 2141
U.S. +1 215 867 4948

Jazz Pharmaceuticals Logo

Logo - https://mma.prnewswire.com/media/272253/Jazz_Pharmaceuticals_Logo.jpg

Voltar noticias em Inglês